Celcuity posts better-than-expected Q4 adjusted net loss
Overview
U.S. biotech firm's Q4 adjusted EPS comes in better than expectations
Adjusted net loss for Q4 also comes in better than analyst expectations
Outlook
Celcuity expects topline results from PIK3CA mutant cohort in Q2 2026
Company preparing for potential commercial launch of gedatolisib in Q3 2026
Result Drivers
R&D AND LAUNCH COSTS - Higher Q4 operating expenses driven by increased R&D and commercial launch-related activities
HIGHER G&A EXPENSES - Increase in G&A expenses mainly due to higher employee-related and consulting costs, including non-cash stock-based compensation
Company press release: ID:nGNX65pryF
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Adjusted EPS | Beat | -$0.73 | -$1.04 (10 Analysts) |
Q4 EPS |
| -$0.97 |
|
Q4 Adjusted Net Income | Beat | -$38.4 mln | -$47.76 mln (9 Analysts) |
Q4 Net Income |
| -$51 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Celcuity Inc is $120.00, about 17.6% above its March 24 closing price of $102.01
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
